Recent

% | $
Quotes you view appear here for quick access.

MannKind Corp. Message Board

  • la_lost_boy la_lost_boy Aug 15, 2013 9:00 PM Flag

    Extremely positive P3 trial results

    What more could anyone had hoped for?
    Sell off = buying opportunity

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • For instance, type 1 diabetics in the Afrezza group failed to hit the key target A1c levels, a long-term measure of blood sugar levels. Doctors like to see patients get their A1c levels below 7%, but the portion of the patients who reached the target was higher in the group taking Novo Nordisk's (NYSE: NVO ) injected insulin Novolog than the Afrezza group. The proportion getting under 6.5% also favored the Novolog group.

      BAD

      The number of severe hypoglycemia events, extremely low blood sugar, in type 1 diabetics was lower in the Afrezza group than those taking Novolog, but it wasn't statistically significant, so MannKind won't be able to tout it as an advantage.

      BAD

      In type 2 diabetics, Afrezza caused more hypoglycemic events than the placebo, which isn't all that surprising, but will clearly be a factor for whether doctors are willing to prescribe it earlier in the disease progression than they would Novolog or Eli Lilly's (NYSE: LLY ) injected insulin Humalog.

      BAD

      Patients taking placebo also lost more weight than the group taking Afrezza

      BAD

      - but the data might not be convincing enough to justify the early use of Afrezza.

      BAD

      TO MUCH BAD TO RAISE PPS MORE

 
MNKD
0.9907+0.0078(+0.79%)Jul 26 4:00 PMEDT